- Open Access
Bioenergetics of murine lungs infected with respiratory syncytial virus
© Alsuwaidi et al.; licensee BioMed Central Ltd. 2013
- Received: 25 August 2012
- Accepted: 11 January 2013
- Published: 15 January 2013
Cellular bioenergetics (cellular respiration and accompanying ATP synthesis) is a highly sensitive biomarker of tissue injury and may be altered following infection. The status of cellular mitochondrial O2 consumption of the lung in pulmonary RSV infection is unknown.
In this study, lung fragments from RSV-infected BALB/c mice were evaluated for cellular O2 consumption, ATP content and caspase activity. The disease was induced by intranasal inoculation with the RSV strain A2 and lung specimens were analyzed on days 2–15 after inoculation. A phosphorescence O2 analyzer that measured dissolved O2 concentration as a function of time was used to monitor respiration. The caspase-3 substrate analogue N-acetyl-asp-glu-val-asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) was used to monitor intracellular caspases.
O2 concentration declined linearly with time when measured in a sealed vial containing lung fragment and glucose as a respiratory substrate, revealing its zero-order kinetics. O2 consumption was inhibited by cyanide, confirming the oxidation occurred in the respiratory chain. Cellular respiration increased by 1.6-fold (p<0.010) and ATP content increased by 3-fold in the first week of RSV infection. Both parameters returned to levels found in uninfected lungs in the second week of RSV infection. Intracellular caspase activity in infected lungs was similar to uninfected lungs throughout the course of disease.
Lung tissue bioenergetics is transiently enhanced in RSV infection. This energy burst, triggered by the virus or virus-induced inflammation, is an early biomarker of the disease and may be targeted for therapy.
- Respiratory syncytial virus (RSV)
- Cellular respiration
- Oxygen consumption
- Cellular ATP
Human respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia worldwide, infecting nearly all children by 2 years of age . Severe disease occurs in premature infants and individuals with compromised respiratory, cardiac or immune system [2, 3]. Furthermore, exposure to RSV early in life may predispose susceptible individuals to asthma .
RSV belongs to the Parmyxoviridae family of enveloped RNA viruses, specifically the genus Pneumovirus. Initially isolated from a chimpanzee, RSV can be found in ruminants, such as sheep, goats and cattle; its main host, however, is humans. The virus has a negative-stranded RNA genome that codes for 10 proteins, including 4 nucleocapsid proteins (N, P, L and M2-1; necessary for RNA replication) and 3 envelope transmembrane proteins (G, F and SH; responsible for virus attachment, membrane fusion, entry and syncytium formation) . The surface fusion protein F and the glycoprotein G serve as the two main targets for antibodies. Variability in the G glycoprotein is primarily responsible for the two clinical strains of RSV, the subgroups A and B . These two subgroups differ mainly in the extracellular domains of G and the small hydrophobic protein SH. Based on sequence variability of the G protein hypervariable region, the subgroups are further divided into clades. The matrix protein (M) is important for viral RNA packaging, while the non-structural proteins have regulatory activities.
RSV infection produces serum and mucosal immune responses that includes IgM, IgA, IgG and IgE; however, the IgG response is short lived and wanes by one year . The primary immune response is not efficient against the initial infection, but results in an effective memory response against reinfection. In addition, the virus generates CD4 and CD8 T cell responses that result in classical interferon-gamma production. Both the humoral and cell-mediated immune responses play roles in virus clearance, but also contribute to the immunopathology of the respiratory tract.
The pathogenesis of RSV is related to its ability to reach the lower respiratory tract, where it can cause bronchiolitis and pneumonia . The RSV strains differ in their virulence, depending upon critical changes in their viral genomes . Overall, subgroup A causes more illness than subgroup B . In the BALB/c mouse model of RSV infection, the virus causes lower respiratory tract infection, making it a good animal model to study . Of note, wild-type inbred mice are described as semi-permissive hosts for human RSV; a very high intranasal inoculum (105 to 107 plaque-forming units per mouse) is usually administered to cause lower respiratory tract disease signs and symptoms such as weight loss, reduced activity, and ruffled fur . Nevertheless, similar to humans, constriction of the airways by mucus production represents a hallmark of disease in mice. Other findings include epithelial hypersensitivity, inflammation, and infiltration by mononuclear cells [9, 12]. Furthermore, production of IgE antibodies and skewing of the immune response towards higher Th-2 and lower Th-1 cytokines are thought to contribute to asthma symptoms observed in mice and young infants [7, 9].
The molecular pathogenesis of clinically aggressive RSV infection is poorly understood, which partially explains the inability to control the disease at the molecular level [13, 14]. For example, information concerning RSV-induced caspases (a series of cysteine, aspartate-specific proteases that mediates apoptosis) in pneumatocytes is inconsistent, and most studies are performed on cell lines. Early studies in the lung epithelial cell line A549 identified apoptotic mediators in response to RSV (e.g., interleukin-1 converting enzyme and CD95), but apoptosis was detected only in ~15% of infected cells [15, 16]. Using the same cell line, Bitko and Barik showed RSV-induced apoptosis was mediated by caspase-12 (an endoplasmic reticulum stress response caspase) . Additional in vitro data implicated RSV in inducing the anti-apoptotic factor IEX-1L, and that normal signaling through the phosphoinositide 3-kinase pathway blocked RSV-induced apoptosis [17, 18]. The study by Kotelkin et al. found transcriptional activations of pro-apoptotic and anti-apoptotic factors in response to RSV in various cell lines . In another study, RSV induced tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors and elicited apoptosis associated with activation of caspase-8 (receptor-mediated) and caspase-9 (mitochondrial-associated) .
Initiation of apoptosis requires the mitochondria to sense the injury, resulting in leakage of cytochrome c and other small molecular weight pro-apoptotic molecules from the mitochondrial intermembrane space to the cytosol . In the cytosol, cytochrome c binds to the apoptotic protease activating factor-1 (Apaf-1), triggering the caspase cascade. Caspase activation induces mitochondrial perturbations, which involve opening the permeability transition pores and collapsing the electrochemical potential. Thus, induction of apoptosis is linked to mitochondrial dysfunction.
Caspase-3 is also involved in proteolysis of proteins, including poly(ADP ribose) polymerase; it cleaves at the second aspartate in the asp-glu-val-asp sequence. Hence, the synthetic substrate N-acetyl-asp-glu-val-asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) can be used to monitor intracellular caspase-3 activity. The released fluorogenic moiety AMC can be separated on HPLC and detected with a great accuracy .
The term “cellular bioenergetics” refers to the biochemical processes involved in energy metabolism (energy conversion or transformation), and the term “cellular respiration” (mitochondrial oxygen consumption) is used to describe the delivery of metabolites and O2 to the mitochondria, oxidation of reduced metabolic fuels with the passage of electrons to O2, and synthesis of ATP.
Measuring tissue mitochondrial O2 consumption, using the principle that O2 quenches the phosphorescence of palladium II-meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin, has been recently reported [22–25]. This analytical tool allows in vitro monitoring of cellular respiration over several hours. Simultaneous determinations of intracellular ATP and caspase activity, however, are necessary, since uncoupling oxidative phosphorylation (accelerated respiration with collapsing cellular ATP) is common after tissue collection. Moreover, caspases are potent inhibitors of the inner mitochondrial membrane function. Therefore, the three parameters (respiration, ATP content and caspase activity) are all necessary for accurate assessment of lung tissue bioenergetics.
The status of lung tissue bioenergetics in RSV infection is currently unknown. It is also unclear whether RSV infection induces pneumatocyte apoptosis and mitochondrial perturbation. Using assays described by us [22–26], these unmet tasks are addressed in this study using a well-established RSV-mouse model system .
Pd(II) complex of meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin ( Pd phosphor) was purchased from Porphyrin Products (Logan, UT). A lyophilized powder of caspase inhibitor I [N-benzyloxycarbonyl-val-ala-asp(O-methyl)-fluoromethylketone; zVAD-fmk; m.w. = 467.5; pan-caspase inhibitor] was purchased from Calbiochem (La Jolla, CA). Ac-DEVD-AMC (N-acetyl-asp-glu-val-asp-7-amino-4-methylcoumarin; m.w. = 675.64; caspase-3 substrate) was purchased from Axxora LLC (San Diego, CA). Glucose (anhydrous) and remaining reagents were purchased from Sigma-Aldrich (St. Louis, MO). HEp-2 and Vero cells were obtained from American Type Culture Collection (ATCC; Manassas, VA).
zVAD-fmk (2.14 mM) solution was made by dissolving 1.0 mg in 1.0 mL dimethyl sulfoxide and stored at −20°C. Ac-DEVD-AMC (7.4 mM) solution was made by dissolving 5.0 mg in 1.0 mL dimethyl sulfoxide and stored at −20°C. Phosphate-buffered saline (PBS) with glucose (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4 and 5 mM glucose, p H 7.4) was made fresh. Pd phosphor solution (2.5 mg/ml = 2 mM) was prepared in dH2O and stored in small aliquots at −20°C. NaCN (1.0 M) was prepared in dH2O; the p H was adjusted to ~7.0 with 12N HCl and stored at −20°C.
RSV strain A2 (RSV-A2) was propagated in the human laryngeal carcinoma cell line, HEp-2 (ATCC). Briefly, cells were grown to ~80% confluence in T-162 flasks and infected with 0.5 ml of ~ 1–2 × 107 plaque-forming units (PFU) per ml with gentle intermittent rocking. Infection was continued at 37°C in a 5% CO2 incubator for two days until peeling of monolayer surfaces and formation of syncytia were observed. Cells were scraped from the flask and sonicated on ice until 85 to 95% of the cells had ruptured, releasing virus into the supernatant. The supernatant was collected by centrifugation at 2500 rpm for 15 min at 4°C, distributed into 500 μl aliquots, snap-frozen in liquid nitrogen and stored at −80°C.
RNA isolation and RT-PCR
RNA was isolated from 20 to 25 mg lung tissue using 1.0 ml TRIZOL reagent (Invitrogen Life Technologies, USA) as per manufacturer’s instruction and stored in ultrapure water at −80°C. For reverse transcription, 5 μg of the extracted lung RNA was DNase-treated with 3 units of RQ1 RNase-free DNase (Promega, Madison, WI) at 37°C for 30 min in the presence of 40 units of Recombinant RNasin (Promega, Madison, WI). The DNased-RNA was RT-PCR amplified with primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to confirm absence of contaminating DNA and converted into cDNA using 300 ng of random hexamers (Metabion, Germany), 400 units of Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega, Madison WI), and 40 units of RNasin in a 50 μL-reaction volume at 37°C for one hr. One μL of the cDNA was used in a 25 μL reaction volume using 20 μL of RT-PCR Supermix High Fidelity (Invitrogen Life Technologies, USA) with 1 μL of 25 mM MgCl2 and 50 ng each of the previously published primers RSVA F and RSVA R . The RT-PCR amplification conditions were as follows: an initial denaturation step at 94°C for 5 min followed by 35 cycles of denaturation at 94°C, annealing at 50°C, and extension at 72°C for 1 min each, and a final extension step at 72°C for 7 min.
Viral stocks were assayed for infectivity using a plaque assay on Vero cells (ATCC) as described previously . Briefly, near confluent Vero cells (90 to 95% cultured in 6-well plates) were infected in duplicate with 100 μl of virus stock diluted from 10-1 to 10-9 in serum-free MEM with intermittent gentle rocking for 90 min. Following infection, the cells were overlaid with 4 ml of a mix of 1% agarose (SeaKem ME agarose; Cambrex) and equal volume of 2x Eagle's Minimal Essential Medium (EMEM; Cambrex). The incubation was continued at 37°C for 5 days before an additional overlay of 2 mL of 1% Seakem ME agarose plus 0.01% neutral red. The plates were left at 25°C to solidify the agarose and then incubated at 37°C for 24 hr. Plaques were counted manually on a light box and the viral titers were expressed as plaque forming units per lung.
Male and female BALB/c mice (4 to 10 weeks old, weight ≈18-22 g) used in this study were purchased from the Jackson Laboratory (Bar Harbor, ME). The mice were housed in a room maintained at 22°C with ~60% relative humidity in compliance with NIH guidelines (http://grants.nih.gov/grants/olaw/references/phspol.htm). All mice had ad libitum access to standard rodent chow and filtered water. All protocols received approval from the Animal Ethics Committee-UAE University-College of Medicine and Health Sciences. At necropsy, lung specimens were processed for histology, plaque assay, RT-PCR, ATP content, O2 consumption and caspase activity.
BALB/c mice were anesthetized by sevoflurane inhalation (100 μL per 10 g). The mice were then inoculated intranasally with 100 μl of RSV-A2 (~ 1–2 × 106 PFU) or mock preparation of HEp-2 culture supernatant.
Lung specimens were collected on various days after inoculation as previously described [22–24] and immediately immersed in ice-cold Krebs-Henseleit (KH) buffer (115 mM NaCl, 25 mM NaHCO3, 1.23 mM NaH2PO4, 1.2 mM Na2SO4, 5.9 mM KCl, 1.25 mM CaCl2, 1.18 mM MgCl2, and 6 mM glucose [pH 7.4]) gassed with 95% O2: 5% CO2. One specimen was immediately transferred to the O2 vial for measuring O2 consumption. Three specimens were immediately processed for ATP measurements. Two specimens were immediately placed in the caspase reactions (with and without zVAD-fmk). Specimens were also processed for histology, RT-PCR and plaque assay.
For histology, specimens were fixed in 4% phosphate-buffered paraformaldehyde and embedded in paraffin wax blocks. Sections of the fixed lung fragments (5–7 μm thickness) were stained with haematoxylin and eosin and examined under a light microscope. For O2 measurements, specimens were placed in 1.0 ml of air-saturated KH buffer containing 0.5% fat-free bovine albumin and 3 μM Pd phosphor. For viral detection, specimens were homogenized in TRIZOL (Invitrogen, USA) and the supernatants stored at −80°C for RNA extraction and RT-PCR.
Phosphorescence O2 analyzer was used to monitor O2 consumption by the lung specimens [22–24]. O2 detection was performed with the aid of Pd phosphor that had absorption maximum at 625 nm and phosphorescence maximum at 800 nm. Samples were exposed to light flashes (600 per min) from a pulsed light-emitting diode array with peak output at 625 nm (OTL630A-5-10-66-E, Opto Technology, Inc., Wheeling, IL). Emitted phosphorescent light was detected by a Hamamatsu photomultiplier tube (928) after first passing it through a wide-band interference filter centered at 800 nm. The amplified phosphorescence decay was digitized at 1.0 MHz by a 20-MHz A/D converter (Computer Boards, Inc., Mansfield, MA).
A program was developed using Microsoft Visual Basic 6, Microsoft Access Database 2007, and Universal Library components (Universal Library for Measurements Computing Devices; http://www.mccdaq.com/daq-software/universal-library.aspx). It allowed direct reading from the PCI-DAS 4020/12 I/O Board (PCI-DAS 4020/12 I/O Board; http://www.mccdaq.com/pci-data-acquisition/PCI-DAS4020-12.aspx). The pulse detection was accomplished by searching for 10 phosphorescence intensities >1.0 volt (by default). Peak detection was accomplished by searching for the highest 10 data points of a pulse and choosing the data point closest to the pulse decay curve .
The phosphorescence decay rate (1/τ) was characterized by a single exponential; I = Ae-t/τ, where I = Pd phosphor phosphorescence intensity . The values of 1/τ were linear with dissolved O2: 1/τ[O2, where 1/τ = the phosphorescence decay rate in the presence of O2, 1/τo = the phosphorescence decay rate in the absence of O2, and kq = the second-order O2 quenching rate constant in s-1 · μM-1.
Lung tissue respiration was measured at 37°C in 1-mL sealed vials. Mixing was with the aid of parylene-coated stirring bars. In vials sealed from air, [O2] decreased linearly with time, indicating the kinetics of mitochondrial O2 consumption was zero-order. The rate of respiration (k, in μM O2 min-1) was thus the negative of the slope d[O2]/dt. Sodium cyanide (NaCN) inhibited respiration, confirming O2 was being consumed in the mitochondrial respiratory chain.
The calibration reaction contained PBS with 3 μM Pd phosphor, 0.5% fat-free albumin, 50 μg/mL glucose oxidase and various concentrations of β-glucose. The values of 1/τ were linear with [β-glucose]; the value of kq was the negative of the slope (kq = 101.1 s-1 · μM-1). The value of 1/τ for air-saturated solution (without glucose) was 28,330 sec-1 (coefficient of variation, Cv = 12%) and for O2-depleted solution (with 500 μM β-glucose, 1/τo) 2,875 s-1 (Cv = 1%). The high values of Cv for the air-saturated solutions were due to the lower phosphorescence intensities with high [O2 (little light reaching the photomultiplier tube). [O2 was calculated using, 1/τ = 1/τo + k q [O2.
Lung tissue fragments were homogenized in 0.5 ml of ice-cold 2% trichloroacetic acid for 2 min. The supernatants were collected by centrifugation (1000xg at 4°C for 5 min) and stored at −20°C until analysis. Immediately before ATP measurements, the samples were neutralized with 0.5 ml 100 mM Tris-acetate, 2 mM EDTA (final pH, 7.75). ATP concentration was determined using the Enliten ATP Assay System (Bioluminescence Detection Kit, Promega, Madison, WI). Briefly, 2.5 μl of the supernatant was added to 25 μl of the luciferin/luciferase reagent. The luminescence intensity was measured at 25°C using Glomax Luminometer (Promega, Madison, WI). The standard was linear with [ATP] (10 pM to 100 nM, R 2 >0.9999).
Lung specimens (~20 mg) were incubated at 37°C in KH buffer continuously gassed with 95% O2: 5% CO2 with and without 32 μM zVAD-fmk for 10 min. Ac-DEVD-AMC (37 μM) was then added and the incubations continued for additional 20 min (final volume, 1.0 ml). The tissue was disrupted by vigorous homogenization and passages through a 27-G needle. The Ac-DEVD-AMC cleavage reaction was quenched with tissue disruption. The supernatant was collected by centrifugation (16,300 g for 90 min) through a Microcentrifuge Filter (nominal molecular weight limit = 10,000 Dalton, Sigma©), separated on HPLC, and analyzed for the free fluorogenic AMC moiety.
The analysis was performed on a Waters 1525 reversed-phase HPLC system (Spectra Lab Scientific Inc., Alexandria, VA) that consisted of a manual injector, pump and fluorescence detector. The excitation wavelength used was 380 nm and the emission wavelength 460 nm. Solvents A and B were HPLC-grade CH3OH:dH2O (1:1; isocratic). The Ultrasphere IP column (4.6 × 250 mm, Beckman) was operated at 25°C at 1.0 ml/min. The run time was 15 min.
Data were analyzed using SPSS statistical package (version 19). The nonparametric test (2 independent variables) Mann–Whitney was used to compare infected and uninfected samples.
A positive control for increased lung tissue caspase activity is shown in Figure 2E. Lung sample was collected from an uninfected mouse and incubated in vitro in KH buffer (without gassing with 95% O2: 5% CO2) for 0, 2 and 6 h. Under this condition, intracellular caspases are typically induced by 2 h (personal observation). The AMC peak area (arbitrary units ÷ 106 ÷ specimen weight in mg) at 0 h (immediately post tissue collection) was 0.5, at 2 h was 3.4 and at 6 h was 6.5. Thus, the amounts of AMC moieties shown in panels A-D for infected and uninfected lungs were relatively negligible. The same results were confirmed in 10 independent experiments spanning the course of the disease over 12 to 15 days as shown in the examples below.
In infected lungs, rates of respiration and ATP contents were higher on days 2 and 5 than days 8, 12 and 15 (Figure 3, Panels A, B and D). By contrast, the values of k c and ATP in uninfected lungs were stable from days 2 to 15 (Figure 3C). The relatively low values of k c and ATP on day 8 were confirmed in an independent experiment, showing k c = 0.08 μM O2 min-1 mg-1 for uninfected lung and k c = 0.06 μM O2 min-1 mg-1 for infected lung. Of note, the value of k c was similar in infected and uninfected lungs on day 1 after inoculation (0.11 and 0.10, respectively). The AMC peak areas on days 2, 5, 8, 12 and 15 after inoculation with RSV-A2 (Figure 3F) were similar to those after inoculation with mock preparation of HEp-2 culture supernatant (Figure 3E).
Similar results were observed in another experiment that measured lung respiration, ATP content and caspase activity in infected and uninfected lungs on days 3, 5, 7, and 10 after inoculation (data not shown). For days 3, 5 and 7 after inoculation, the values of k c in uninfected lungs were 0.057 ± 0.020 μM O2 min-1 mg-1 and in infected lungs 0.107 ± 0.035 μM O2 min-1 mg-1. On day 10, the value of k c was 0.090 μM O2 min-1 mg-1 in both infected and uninfected lungs. Similarly, ATP contents in infected lungs were higher than uninfected lungs and caspase activity was negligible.
Further confirmation of the presence of infectious virus was revealed by the plaque assay . Whole lung titers (tested on days 2, 5, 8 and 10) showed a peak on day 5 with 3 × 102 PFU/lung, while day 8 showed a titer of 2 × 101 PFU/lung. The titers for days 2 and 10 remained below the sensitivity of the assay. These results confirmed the RT-PCR results that the infection peaked on day 5. Similar kinetics of infection has been observed with RSV patient isolates tested in BALB/c mice, where the viral load in the lung peaked on day 4 post-intranasal inoculation of 6–8 week old mice using 105 PFU .
The studied murine model shows a transient enhancement of lung tissue bioenergetics (increased cellular mitochondrial O2 consumption and ATP content) in the first week of RSV infection (Figure 1 and 3). As previously shown, reproduction of viral particles is highly dependent on host energy metabolism and metabolic fuels are essential for viral survival . Thus, the data suggest that increased pneumatocyte energy conversion (ATP production) is required early in RSV infection to sustain active viral replication.
As shown in Figure 3, cellular ATP in infected lung tissues increased by ~3-fold on days 2 to 5 after inoculation. This finding is consistent with the study of Davis et al. showing a 2-fold increase of nucleotide levels (ATP and UTP) in bronchoalveolar lavage fluid of RSV infected BALB/c mice on day 2. Moreover, inhibition of de novo pyrimidine synthesis with leflunomide resulted in reduction of UTP and ATP in the bronchoalveolar lavage fluid, which reversed impaired alveolar fluid clearance, edema and hypoxemia. Thus, understanding the metabolic energy flow may be useful in combating RSV infection .
Consistently, hepatitis C virus was found to utilize host lipid metabolism for its survival in a way that promotes liver injuries . Moreover, anti-HCV therapies directed specifically at host metabolic pathways have been successfully developed , which highlights the therapeutic potentials of targeting host metabolic pathways to halt viral replication.
Cellular mitochondrial O2 consumption and ATP synthesis are linked to the entire metabolism. Therefore, these biomarkers are highly sensitive for detecting changes in cellular energy processes. Both parameters are used here to show increased energy expenditure (requirement) in RSV infected lungs.
The virus or its associated cytokines could drive the observed high-energy demand early in the course of RSV infection. Since viruses typically utilize host resources, it is likely that RSV transforms pneumatocyte metabolism favoring viral survival. The RSV load dynamics, measured by plaque assay in BAL samples of mice, was investigated in one study. RSV load peaked on days 3 to 5 after inoculation (representing active viral replication) and was not detectable on day 7 and thereafter . These results suggest that a high-energy requirement is needed during RSV load peak in the first week of infection. Thus, the energy profiles shown in Figure 3 coincide with the RSV replication and returns to normal state after viral replication ceases. Of note, lung tissue TNF-α Peribronchiolar and peribronchial and INF-γ levels both peaked on day 5 (data not shown).
Peribronchiolar and peribronchial infiltrates were noticeable only on days 8, 12 and 15 after inoculation (Figure 4); that is, after the energy burst. Enhanced (about 40%) cellular mitochondrial oxygen consumption rate was also noted in cultured HEp-2 cells 90 min after the addition of RSV strain A2 (data not shown).
In this model, caspase activity was not noted in the lung tissue during the studied course of RSV infection (Figure 2). This finding correlates with the mild disease observed histologically (Figure 4). Virus strain, inoculation dose and host factors (BALB/c mice are semi-permissive to human RSV infection) are potential contributors to the observed benign disease. It remains to be seen, however, if manipulating these variables will result in infection with increased caspase activity. Alternatively, caspase induction may require a co-infection with bacteria. Substantial caspase activity will impair mitochondrial function and deplete cellular ATP, an event that inevitably leads to cell death. This fact reflects the dependency of mammalian energy supply on aerobic metabolism. Therefore, absence of apoptosis and intact pneumatocyte bioenergetics are favorable prognostic biomarkers.
It is unclear how cellular respiration is accelerated in RSV infected lungs. It is also unknown whether these results are specific for RSV or can be seen with other viruses. Of note, this mechanism could not be investigated in vitro since the rate of respiration increased about 4-fold in samples incubated in vitro for ≤4 h (Additional file 1: Table S1). This finding most likely reflected uncoupling oxidative phosphorylation as evidenced by the sharp decline in cellular ATP in vitro (data not shown).
Nevertheless, the mechanism of accelerated respiration in infected lung was further investigated as follows. First, cellular ATP was also increased in infected lung indicating that the increased energy expenditure was not due to uncoupling oxidative phosphorylation. Second, in glucose-free media, cellular respiration was halted sooner in infected lungs indicating more rapid depletion of the endogenous metabolic fuels in RSV infected lungs. In glucose-free media, the value of k c for uninfected lung tissue was 0.05 μM O2 min-1 mg-1 and remained the same after the addition of 10 mM glucose at t = 50 min. The corresponding values for the RSV infected lung were 0.05 and 0.13, respectively. Therefore, the accelerated respiration in RSV infected was dependent on exogenous glucose as a respiratory substrate.
It is still unclear how the RSV infection could regulate lung tissue cellular energy conversion. Potential mechanisms may include increasing delivery of metabolic fuels to host pneumatocyte, up regulating metabolic enzymes, and preventing inhibitory (regulatory) steps in energy pathways. As noted above for hepatitis C, it remains to be seen whether these biomarkers can be targeted for therapy.
This work was supported by a grant from the UAE University.
- Mejias A, Chavez-Bueno S, Jafri HS, Ramilo O: Respiratory syncytial virus infections: old challenges and new opportunities. Pediatr Infect Dis J 2005,24(11 Suppl):S189. discussion S96-7PubMedView ArticleGoogle Scholar
- Beckham JD, Cadena A, Lin J, Piedra PA, Glezen WP, Greenberg SB, et al.: Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect 2005, 50: 322-330. 10.1016/j.jinf.2004.07.011PubMedView ArticleGoogle Scholar
- Welliver RC: Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003, 143: S112-S117. 10.1067/S0022-3476(03)00508-0PubMedView ArticleGoogle Scholar
- Mohapatra SS, Boyapalle S: Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev 2008, 21: 495-504. 10.1128/CMR.00054-07PubMedPubMed CentralView ArticleGoogle Scholar
- Collins PL, Crowe JE, Knipe DM, Howley PM, et al.: Respiratory syncytial virus and metapneumovirus. In Fields virology. 5th edition. Edited by: Knipe DM. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1601-1646.Google Scholar
- Cane PA: Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 2001, 11: 103-116. 10.1002/rmv.305PubMedView ArticleGoogle Scholar
- Junge S, Nokes DJ, Simoes EAF, Weber MW: Respiratory syncytial virus. City, state: Elsevier Inc; 2008:561-571.Google Scholar
- van Drunen S, van den Hurk L, Watkiss ER: Pathogenesis of respiratory syncytial virus. Curr Opinion Virol 2012, 2: 300-305. 10.1016/j.coviro.2012.01.008View ArticleGoogle Scholar
- Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, Hotard A, Sherrill TP, Peebles RS, Moore MM: Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 2011, 85: 5782-5793. 10.1128/JVI.01693-10PubMedPubMed CentralView ArticleGoogle Scholar
- Hall CB: Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001, 344: 1917-1928. 10.1056/NEJM200106213442507PubMedView ArticleGoogle Scholar
- Bem RA, Domachowske JB, Rosenberg HF: Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 2011,301(2):148-156. 10.1152/ajplung.00065.2011View ArticleGoogle Scholar
- Han J, Takeda K, Gelfand EW: The role of RSV infection in asthma initiation and progression: findings in a mouse model. Pulmonary Med 2011. doi:10.1155/2011/748038Google Scholar
- Boya P, Roques B, Kroemer G: New EMBO members' review: viral and bacterial proteins regulating apoptosis at the mitochondrial level. EMBO J 2001, 15: 4325-4331.View ArticleGoogle Scholar
- Arnoult D, Carneiro L, Tattoli I, Girardin SE: The role of mitochondria in cellular defense against microbial infection. Semin Immunol 2009, 21: 223-232. 10.1016/j.smim.2009.05.009PubMedView ArticleGoogle Scholar
- Takeuchi R, Tsutsumi H, Osaki M, Haseyama K, Mizue N, Chiba S: Respiratory syncytial virus infection of human alveolar epithelial cells enhances interferon regulatory factor 1 and interleukin-1β-converting enzyme gene expression but does not cause apoptosis. J Virol 1998, 72: 4498-4502.PubMedPubMed CentralGoogle Scholar
- O'Donnell DR, Milligan L, Stark JM: Induction of CD95 (Fas) and apoptosis in respiratory epithelial cell cultures following respiratory syncytial virus infection. Virology 1999, 257: 198-207. 10.1006/viro.1999.9650PubMedView ArticleGoogle Scholar
- Bitko V, Barik S: An endoplasmic reticulum-specific stress-activated caspase (caspase-12) is implicated in the apoptosis of A549 epithelial cells by respiratory syncytial virus. J Cell Biochem 2001, 80: 441-454. 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-CPubMedView ArticleGoogle Scholar
- Domachowske JB, Bonville CA, Mortelliti AJ, Colella CB, Kim U, Rosenberg HF: Respiratory syncytial virus infection induces expression of the anti-apoptosis gene IEX-1L in human respiratory epithelial cells. J Infect Dis 2000, 181: 824-830. 10.1086/315319PubMedView ArticleGoogle Scholar
- Kotelkin A, Prikhod'ko EA, Cohen JI, Collins PL, Bukreyev AJ: Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. Virology 2003, 77: 9156-72. 10.1128/JVI.77.17.9156-9172.2003View ArticleGoogle Scholar
- Thomas KW, Monick MM, Staber JM, Yarovinsky T, Carter AB, Hunninghake GW: Respiratory syncytial virus inhibits apoptosis and induces NF-kappa B activity through a phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem 2002, 277: 492-501.PubMedView ArticleGoogle Scholar
- Green DR, Kroemer G: The pathophysiology of mitochondrial cell death. Science 2004, 305: 626-629. 10.1126/science.1099320PubMedView ArticleGoogle Scholar
- Tao Z, Penefsky HS, Goodisman J, Souid A-K: Caspase activation by cytotoxic drugs (the caspase storm). Mol Pharm 2007, 4: 583-595. 10.1021/mp070002rPubMedView ArticleGoogle Scholar
- Al Samri MT, Al Shamsi M, Al-Salam S, Marzouqi F, Al Mansouri A, Al-Hammadi S, Balhaj G, Al Dawaar SK, Al Hanjeri RS, Benedict S, Sudhadevi M, Conca W, Penefsky HS, Souid A-K: Measurement of oxygen consumption by murine tissues in vitro. J Pharmacol Toxicol Meth 2011, 63: 196-204. 10.1016/j.vascn.2010.10.002View ArticleGoogle Scholar
- Al-Shamsi M, Al-Samri M, Al-Salam S, Conca W, Benedict S, Sudhadevi M, Biradar A, Asefa T, Souid A-K: Biocompatibility study of mesoporous silicate particles with cellular bioenergetics in murine tissues. Chem Res Toxicol 2010, 11: 1796-1805.View ArticleGoogle Scholar
- Al-Salam S, Balhaj G, Al-Hammadi S, Sudhadevi M, Tariq S, Biradar AV, Asefa T, Souid A-K: In vitro study of calcined mesoporous silica nanoparticles in mouse lung. Toxicology Sciences 2011, 122: 86-99. 10.1093/toxsci/kfr078View ArticleGoogle Scholar
- Shaban S, Marzouqi F, Al Mansouri A, Penefsky H, Souid AK: Oxygen measurements via phosphorescence. Computer Meth Programs Biomed 2010, 100: 265-268. 10.1016/j.cmpb.2010.04.009View ArticleGoogle Scholar
- Olsen MR, Varga SM: CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 2007, 179: 5415-5424.View ArticleGoogle Scholar
- Lo LW, Koch CJ, Wilson DF: Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra (4-carboxyphenyl) porphine: A phosphor with general application for measuring oxygen concentration in biological systems. Anal Biochem 1996, 236: 153-160. 10.1006/abio.1996.0144PubMedView ArticleGoogle Scholar
- Stockton J, Ellis JS, Saville M, Clewley JP, Zambon MC: Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. J Clin Microbiol 1998, 36: 2990-2995.PubMedPubMed CentralGoogle Scholar
- Fulton RB, Meyerholz DK, Varga SM: Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol 2010, 185: 2382-2392. 10.4049/jimmunol.1000423PubMedPubMed CentralView ArticleGoogle Scholar
- Maynard ND, Gutschow MV, Birch EW, Covert MW: The virus as metabolic engineer. Biotechnol J 2010, 5: 686-694. 10.1002/biot.201000080PubMedPubMed CentralView ArticleGoogle Scholar
- Davis IC, Lazarowski ER, Hickman-Davis JM, Fortenberry JA, Chen FP, Zhao X, Sorscher E, Graves LM, Sullender WM, Matalon S: Leflunomide prevents alveolar fluid clearance inhibition by respiratory syncytial virus. Am J Respir Crit Care Med 2006,15(173):673-682.View ArticleGoogle Scholar
- Syed GH, Amako Y, Siddiqui A: Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010, 21: 33-40. 10.1016/j.tem.2009.07.005PubMedPubMed CentralView ArticleGoogle Scholar
- Ikeda M, Kato N: Modulation of host metabolism as a target of new antivirals. Adv Drug Deliv Rev 2007,10(59(12)):1277-1289.View ArticleGoogle Scholar
- Chávez-Bueno S, Mejías A, Gómez AM, Olsen KD, Ríos AM, Fonseca-Aten M, Ramilo O, Jafri HS: Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model. Virol J 2005, 2: 46. 10.1186/1743-422X-2-46PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.